Trial Watch: Peptide-based anticancer vaccines
Jonathan Pol1, Norma Bloy2, Aitziber Buqué1
1Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM, U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France.
Abstract:
Malignant cells express antigens that can be harnessed to elicit anticancer immune responses. One approach to achieve such goal consists in the administration of tumor-associated antigens (TAAs) or peptides thereof as recombinant proteins in the presence of adequate adjuvants. Throughout the past decade, peptide vaccines have been shown to mediate antineoplastic effects in various murine tumor models, especially when administered in the context of potent immunostimulatory regimens. In spite of multiple limitations, first of all the fact that anticancer vaccines are often employed as therapeutic (rather than prophylactic) agents, this immunotherapeutic paradigm has been intensively investigated in clinical scenarios, with promising results. Currently, both experimentalists and clinicians are focusing their efforts on the identification of so-called tumor rejection antigens, i.e., TAAs that can elicit an immune response leading to disease eradication, as well as to combinatorial immunostimulatory interventions with superior adjuvant activity in patients. Here, we summarize the latest advances in the development of peptide vaccines for cancer therapy.
Insights
Cancer peptide vaccines harness tumor antigens to stimulate immune responses, showing promise in therapeutic applications. Research focuses on identifying tumor rejection antigens and optimizing adjuvant strategies for enhanced efficacy.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Malignant cells express tumor-associated antigens (TAAs) that can be targeted for immune-mediated anticancer responses.
- Peptide vaccines, using TAAs or their peptides with adjuvants, have demonstrated antineoplastic effects in preclinical models.
- Despite limitations, cancer vaccines are actively investigated clinically, yielding promising therapeutic results.
Approach:
- Administration of tumor-associated antigens (TAAs) or peptides as recombinant proteins with adjuvants.
- Utilizing potent immunostimulatory regimens to enhance vaccine efficacy.
- Focusing on identifying tumor rejection antigens for complete disease eradication.
Key Points:
- Peptide vaccines have shown efficacy in murine tumor models.
- Clinical investigations of cancer vaccines are ongoing with encouraging outcomes.
- Identifying TAAs that elicit potent immune responses is crucial for therapeutic success.
- Combinatorial strategies with superior adjuvants are being explored.
Conclusions:
- Peptide vaccines represent a promising immunotherapeutic approach for cancer treatment.
- Advances in identifying tumor rejection antigens and adjuvant therapies are critical for future development.
- Continued research is essential to overcome limitations and improve the efficacy of cancer peptide vaccines.
More Related Videos
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:21Vaccines
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...